Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation
Αndreas S. Papazoglou, Αναστάσιος Κάρτας, Dimitrios V. Moysidis, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 428
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Trends and disparities in atrial fibrillation‐related mortality among adults with co‐morbid diabetes mellitus in the United States
Usama Qamar, Farhan Naeem, Siddharth Agarwal
European Journal of Clinical Investigation (2025)
Closed Access | Times Cited: 1
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Tze‐Fan Chao, Shao‐Wei Chen, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 28
Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives
Amalia Baroutidou, Nikolaos Otountzidis, Αndreas S. Papazoglou, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 2
Open Access | Times Cited: 5
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1
Richard G. Trohman, Henry D. Huang, Parikshit S. Sharma
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Association between the systemic immune‐inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation
Zhihao Zhao, Baoping Jiang, Fengyun Zhang, et al.
Clinical Cardiology (2023) Vol. 46, Iss. 11, pp. 1426-1433
Open Access | Times Cited: 11
Prognostic value of glycaemic variability for mortality in critically ill atrial fibrillation patients and mortality prediction model using machine learning
Yang Chen, Zheng-kun Yang, Yang Liu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Relationship between elevated serum direct bilirubin and atrial fibrillation risk among patients with coronary artery disease
Yanbin Song, Wenhua Li
Frontiers in Medicine (2025) Vol. 12
Open Access
Prediabetes as a risk factor for new-onset atrial fibrillation: the propensity-score matching cohort analyzed using the Cox regression model coupled with the random survival forest
Jung‐Chi Hsu, Yen‐Yun Yang, Shu‐Lin Chuang, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 10
SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
Yi‐Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Impact of Sodium‐Glucose Co‐Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post‐Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Naser Abdelhadi, Khaled Mohamed Ragab, Mohammed Elkholy, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Associations of glycemic status with dynamic disease trajectories of atrial fibrillation and dementia
Chenglong Li, Daijun He, Yufan Liu, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100047-100047
Open Access
Oral Anticoagulation Choice and Dosage in Very Elderly Patients with Atrial Fibrillation
Martha Zergioti, Melina Kyriakou, Αndreas S. Papazoglou, et al.
Journal of Cardiovascular Development and Disease (2025) Vol. 12, Iss. 3, pp. 86-86
Open Access
Diabetes and Atrial Fibrillation: Insight From Basic to Translational Science Into the Mechanisms and Management
Bharat K. Kantharia, Mohammadreza Tabary, Lingling Wu, et al.
Journal of Cardiovascular Electrophysiology (2025)
Closed Access
Obesity as a risk factor for cardiac arrhythmias
Kiran Haresh Kumar Patel, Rohin K. Reddy, Arunashis Sau, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000308-e000308
Open Access | Times Cited: 16
Metabolic Syndrome and Atrial Fibrillation: Different Entities or Combined Disorders
George Ε. Zakynthinos, Vasiliki Tsolaki, Evangelos Oikonomou, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1323-1323
Open Access | Times Cited: 9
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14704-14704
Open Access | Times Cited: 9
Prognostic Impact of Body Mass Index in Atrial Fibrillation
Maria Nteli, Despoina Nteli, Dimitrios V. Moysidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3294-3294
Open Access | Times Cited: 2
Impact of Diabetes Mellitus on Atrial Fibrillation Recurrence and Major Adverse Cardiac and Cerebrovascular Events following Catheter Ablation
Mingjie Lin, Juntao Wang, Bing Rong, et al.
International Journal of Clinical Practice (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
The Synergistic Relationship Between Atrial Fibrillation and Diabetes Mellitus: Implications for Cardiovascular and Metabolic Health
Maryam Mohsin, Hafiz Zeyad, Hareem Khalid, et al.
Cureus (2023)
Open Access | Times Cited: 6
Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis
Chao Lv, Chongqing Hu, Chuanmeng Zhu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115963-115963
Open Access | Times Cited: 6
Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors – rationale and design of the “Beyond-SMuRFs Study”
Dimitrios V. Moysidis, Stylianos Daios, Vasileios Anastasiou, et al.
BMC Cardiovascular Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Evaluation of Fracture Risk Among Patients With Type 2 Diabetes and Nonvalvular Atrial Fibrillation Receiving Different Oral Anticoagulants
David Tak Wai Lui, Eric Ho Man Tang, Ivan Chi Ho Au, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2620-2627
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top